Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04327934 · ClinicalTrials.gov registry record · Early Phase 1
Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome
A Early Phase 1 study, sponsored by Yale University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 28
- Enrollment target
NCT04327934 is a Early Phase 1 study that was terminated before completion, run by Yale University. The registered enrollment target is 28 participants.
The verdict
NCT04327934, a Early Phase 1 study, was terminated before completion, sponsored by Yale University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
Women with androgen excess polycystic ovary syndrome (AE-PCOS) leads to hypertension.
Interventions
- DRUG GnRH antagonist
- DRUG GnRH antagonist + MethylTESTOSTERone 5 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2022-06-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04327934
The ClinicalTrials.gov registry entry for NCT04327934 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GnRH antagonist is the first listed.
NCT04327934 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04327934 about?
NCT04327934 is a clinical study titled "Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome". Women with androgen excess polycystic ovary syndrome (AE-PCOS) leads to hypertension.
What is the current status of trial NCT04327934?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 28 participants. The study started on 2017-12-01. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT04327934?
The interventions under investigation include: GnRH antagonist (DRUG), GnRH antagonist + MethylTESTOSTERone 5 MG (DRUG).
Who is sponsoring clinical trial NCT04327934?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.